SHANGHAI HEARTCARE MEDICAL TECHNOLOGY CORPORATION LIMITED

Ratings Shanghai HeartCare Medical Technology Corporation Limited

Equities

6609

CNE100004MN5

Market Closed - Hong Kong S.E. Other stock markets 04:08:17 2024-05-17 am EDT			5-day change	1st Jan Change
18.56 ^HKD	0.00%		-4.13%	-37.61%

Mar. 28	Shanghai HeartCare Medical Technology Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Shanghai HeartCare Offloads Stake in Medical Device Developer Shenji Medical	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Thanks to a sound financial situation, the firm has significant leeway for investment.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.69 for the 2024 fiscal year.
The company appears to be poorly valued given its net asset value.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 928 times its estimated earnings per share for the ongoing year.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
SHANGHAI HEARTCARE MEDICAL TECHNOLOGY CORPORATION LIMITED	-37.61%	90.74M	-
ABBOTT LABORATORIES	-5.43%	181B	C+
MEDTRONIC PLC	+4.30%	114B	C
BECTON, DICKINSON AND COMPANY	-3.09%	68.29B	A
DEXCOM, INC.	+5.86%	52.24B	B-
CENCORA, INC.	+8.15%	44.3B	B-
HOYA CORPORATION	+7.52%	42.73B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+25.54%	32.52B	B
TERUMO CORPORATION	+17.85%	26.02B	A-
WEST PHARMACEUTICAL SERVICES, INC.	+1.00%	25.91B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes